<SEC-DOCUMENT>0001628280-22-018303.txt : 20220701
<SEC-HEADER>0001628280-22-018303.hdr.sgml : 20220701
<ACCEPTANCE-DATETIME>20220630173502
ACCESSION NUMBER:		0001628280-22-018303
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20220701
DATE AS OF CHANGE:		20220630

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		221058908

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>ardx-20220630xdefa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4ec5dcd8257f4411bd59017229d51ef8_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div id="i4ec5dcd8257f4411bd59017229d51ef8_4"></div><div style="margin-top:9pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">UNITED STATES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SECURITIES AND EXCHANGE COMMISSION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Washington, DC 20549 </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:210.85pt;padding-right:210.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:80%">&#160;</font></div></td></tr></table></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:100%">SCHEDULE 14A </font></div><div style="margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Proxy Statement Pursuant to Section&#160;14(a) of the </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Securities Exchange Act of 1934 </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Amendment No.&#160;&#160;&#160;&#160;) </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:2pt;padding-left:210.85pt;padding-right:210.85pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:80%">&#160;</font></div></td></tr></table></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filed by the Registrant&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Filed by a Party other than the Registrant&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </font></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Check the appropriate box&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#160;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.710%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preliminary Proxy Statement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Confidential, for Use of the Commission Only&#160;(as permitted by Rule 14a-6(e)(2))</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definitive Proxy Statement</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Definitive Additional Materials</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Soliciting Material under &#167;240.14a-12</font></td></tr></table></div><div style="margin-top:7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:100%">Ardelyx, Inc. </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Name of Registrant as Specified in its Charter) </font></div><div style="margin-top:7pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </font></div><div style="margin-top:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment of Filing Fee (Check all boxes that apply)&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No fee required.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee paid previously with preliminary materials.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="margin-top:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><img alt="image_0.jpg" src="image_0.jpg" style="height:79px;margin-bottom:5pt;vertical-align:text-bottom;width:79px"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ARDELYX, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On June 30, 2022, Ardelyx, Inc. mailed a letter to Stockholders</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> urging Stockholders to vote &#8220;</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR</font><font style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; each of the proposals being submitted to a vote at the Ardelyx Annual Meeting of Stockholders.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full text of the letter follows&#58;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">*******</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">June 28, 2022</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Dear Ardelyx, Inc. Stockholder&#58;</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">You should have already received proxy materials related to Ardelyx Inc.&#8217;s annual stockholder meeting which has been adjourned to July 13, 2022.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The remaining proposal before the stockholders is proposal #2, granting our Board of Directors authority to affect a reverse stock split of our authorized common stock and issued and outstanding common stock by amending our Amended and Restated Certificate of Incorporation by September 15, 2022, and within a range of not less than 1-for-2 and not more than 1-for-10, if our Board of Directors deems it within our best interests. As reported in our Form 8-K filed on June 22, 2022, as of June 15, 2022, the date of our annual stockholder meeting, support for proposal #2 was approximately 66.74% of the votes cast on the proposal. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">As discussed in the proxy materials, our primary objective in asking for the authority to affect the reverse stock split is to raise the per share trading price of our common stock. The board believes that having the ability to implement the reverse stock split would better enable us to maintain the listing of our common stock on the Nasdaq Global Market. Also, if the reverse stock split is implemented, we believe it would facilitate higher levels of institutional stock ownership, where investment policies generally prohibit investments in lower-priced securities and better enable us to raise funds to finance operations.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">While we intend to monitor the closing price of our common stock and consider available options depending on the trading price of our common stock, no assurance can be made that we will in fact be able to continue to comply. If an issuer&#8217;s equity security is delisted from Nasdaq, it may be forced to seek to have its equity security traded or quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; Such alternatives are generally considered to be less efficient markets and not as broad as Nasdaq, and therefore less desirable. Accordingly, the delisting, or even the potential delisting, of an equity security could have a negative impact on the liquidity and market price of the equity security. As such, our Board believes that it is in the best interest of the Company and its stockholders that the Board has the ability to affect, in its discretion, the reverse stock split to improve the price level of our common stock so that we are able to maintain continued compliance with the Bid Price Rule and minimize the risk of future delisting from Nasdaq. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">A reverse stock split, if approved and affected, would have the result of each stockholder owning a reduced number of shares of common stock. However, the reverse stock split would affect all stockholders uniformly and would not affect the stockholder&#8217;s percentage ownership interest in the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Company. Proportionate voting rights and other rights and preferences of the holders of common stock would not be affected by the reverse stock split. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">We are writing to you to ask for your support for this proposal. Although, two-thirds of the stockholders who voted on this proposal #2 as of the date of the annual stockholder meeting voted in favor of this proposal, this proposal requires the affirmative vote of a majority of the common stock outstanding and eligible to vote. We urge you to take a moment and cast your vote in support of proposal #2. Your support would be very much appreciated.</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%">There are three ways to vote your shares of ARDX common stock- each only taking a few moments&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">By Telephone &#8211; Stockholders in the United States can submit their vote by calling the toll-free number indicated on the enclosed vote instruction form&#59; please have your control number located on the enclosed vote instruction form available when calling&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">By Internet &#8211; Stockholders can submit their vote via internet at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">www.proxyvote.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#59; please have the control number located on the enclosed vote instruction form available&#59; or</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:14.15pt">By Mail &#8211; Stockholders can vote by mail by signing, dating and returning the enclosed vote instruction form in the postage-paid envelope provided.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To be valid, your vote by telephone or internet must be received by 11&#58;59 p.m. (Eastern Time) on July 12, 2022, the day preceding the annual meeting of stockholders. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If you need assistance in voting your shares or have questions regarding the annual meeting of stockholders, please contact ARDX&#8217;s proxy solicitor, MacKenzie Partners, Inc., at (800) 322-2885 (toll-free) or (212) 929-5500 (collect), or email at proxy&#64;mackenziepartners.com.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">We thank you for your continued support of ARDX.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sincerely,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ardelyx, Inc.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">If you have questions or need assistance in voting your shares, please contact&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1407 Broadway, 27</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> Floor</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">New York, New York 10018</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">(212) 929-5500 or</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Call Toll-Free (800) 322-2885</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                              </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Email&#58; proxy&#64;mackenziepartners.com</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*******</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">About Ardelyx, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (tenapanor) is available in the United States. Ardelyx is developing XPHOZAH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and&#47;or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Forward Looking Statements</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">To the extent that statements contained in this communication are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including statements regarding the anticipated effects of stockholder approval of the reverse stock split and the failure to receive such stockholder approval. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those risks and uncertainties that are described in the definitive proxy statement filed with the Securities and Exchange Commission on April 29, 2022. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 5, 2022, and its future current and periodic reports to be filed with the Securities and Exchange Commission.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_0.jpg
<TEXT>
begin 644 image_0.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_[0 V4&AO=&]S:&]P(#,N,  X0DE- ^T*
M4F5S;VQU=&EO;@     0 ,     !  $ P     $  ?_B"^!)0T-?4%)/1DE,
M10 ! 0  "]!N;VYE @   &UN=')21T(@6%E:( ?4  < %0 3  L (6%C<W
M         $E%0R!S4D="     0            #VU@ !     -,M2% @(
M
M$&1E<V,   %$    =&)865H   &X    %&)44D,   ',   (#&1M9&0   G8
M    B&=865H   I@    %&=44D,   ',   (#&QU;6D   IT    %&UE87,
M  J(    )&)K<'0   JL    %')865H   K     %')44D,   ',   (#'1E
M8V@   K4    #'9U960   K@    AW=T<'0   MH    %&-P<G0   M\
M*&-H860   ND    +&1E<V,         &G-21T(@245#-C$Y-C8M,BTQ('=I
M=&A"4$,
M                                                    6%E:(
M     "2@   /A   ML]C=7)V        !      %  H #P 4 !D '@ C "@
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M;W5R(%-P86-E("T@<U)'0@
M
M      !865H@        8ID  +>%   8VEA96B            !0
M;65A<P         !                               "6%E:(
M  ,6   #,P   J1865H@        ;Z(  #CU   #D'-I9R      0U)4(&1E
M<V,         +5)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,@
M-C$Y-C8M,BTQ
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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MKHA^41:YX?NC)I>H@PM)!'<RVXO[..61]/O+.<K,O[_?LH_\%'_AW\=KK2O
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M^:9W7E.64Y?4A-<E;#T'0JYCC:?[R,EA\+A<12E1Q[9Y-1117^*Q_KD%%%%
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M<E?FJRBY3<7.7U/^Q'XE7PI^UC\"M4<[5N?'5EX;S@'GQE:WGA!<YF@ !;7
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M141W,D5R\85'.[Y&QY;<V=W9LJ7=K<VK."R+<P2P,Z@X+*)54L >"0",\5^
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M2RL\C,QWZ_T3\&?H7< >&^(PF?\ %=:/'W%6&E2Q&&GCL)'#\.Y3B:;52%7
M9/*I7>-Q-"II3QV:5J\5*%+$X7+\!B8*2_A#Q:^EMQMQ_0Q.2<,T9<$\-8B-
M2CB(8/%2KY]F>'FN25/&YI&%%83#UH:SP>74J,N6=3#XC&XVA*S****_LT_D
'P**** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
